Cargando…

Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina

OBJECTIVE: There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and virologic outcomes in patients exposed to FDC DRV/r + raltegra...

Descripción completa

Detalles Bibliográficos
Autores principales: Rombini, Fernanda, Cecchini, Diego M., Ballivian, Jamile, Huberman, Mara, Urueña, Analía, Cassetti, Isabel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedad Española de Quimioterapia 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876904/
https://www.ncbi.nlm.nih.gov/pubmed/33267555
http://dx.doi.org/10.37201/req/090.2020
_version_ 1783650056941862912
author Rombini, Fernanda
Cecchini, Diego M.
Ballivian, Jamile
Huberman, Mara
Urueña, Analía
Cassetti, Isabel
author_facet Rombini, Fernanda
Cecchini, Diego M.
Ballivian, Jamile
Huberman, Mara
Urueña, Analía
Cassetti, Isabel
author_sort Rombini, Fernanda
collection PubMed
description OBJECTIVE: There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and virologic outcomes in patients exposed to FDC DRV/r + raltegravir (RAL) 400 mg every 12 h in a real-life setting. PATIENTS AND METHODS: . Retrospective analysis of electronic medical records of HIV-infected patients under FDC DRV/r + RAL in an HIV clinic in Argentina (2014-2018). Individuals were classified as “switch group” (SG, undetectable viral load [VL] with any toxicity/comorbidity) and “virologic group• (VG, detectable viremia and infection by multidrug-resistant HIV). RESULTS: Of 7,380 patients on ART, 116 (1.5%) received FDC DRV/r + RAL, being 58% in SG. Sixty percent received DRV/r 800/100 mg dose (rest, 600/100 mg). The median (IQR) age and CD4+ T-cell count were: 52 (42-58) years, and 373 cell/µL (202-642). Ninety-eight percent were ART-experienced with a median of 3 (IQR 2-5) prior treatments. Main reasons for switch (SG) were renal (57%), cardiovascular (54%) and bone (14%) comorbidities. Median exposure to DRV/r + RAL was 18 months. Among patients in SG, 98% and 96% had undetectable VL at 6 and 12 months; in the VG, 89% and 87% had undetectable VL at 6 and 12 months. No patient required suspension due to toxicity/ intolerance. CONCLUSION: In this cohort of mostly experienced HIV-infected patients, FDC DRV/r + RAL was effective and safe. Such therapy may be considered an option for patients with comorbid conditions and/or with multidrug-resistant HIV.
format Online
Article
Text
id pubmed-7876904
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Sociedad Española de Quimioterapia
record_format MEDLINE/PubMed
spelling pubmed-78769042021-02-22 Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina Rombini, Fernanda Cecchini, Diego M. Ballivian, Jamile Huberman, Mara Urueña, Analía Cassetti, Isabel Rev Esp Quimioter Brief Report OBJECTIVE: There are generic fixed-dose combinations (FDCs) of ritonavir-boosted darunavir (DRV/r) available in Argentina. Experiences with these FDCs in dual therapy remain limited in clinical practice. We aimed to describe clinical and virologic outcomes in patients exposed to FDC DRV/r + raltegravir (RAL) 400 mg every 12 h in a real-life setting. PATIENTS AND METHODS: . Retrospective analysis of electronic medical records of HIV-infected patients under FDC DRV/r + RAL in an HIV clinic in Argentina (2014-2018). Individuals were classified as “switch group” (SG, undetectable viral load [VL] with any toxicity/comorbidity) and “virologic group• (VG, detectable viremia and infection by multidrug-resistant HIV). RESULTS: Of 7,380 patients on ART, 116 (1.5%) received FDC DRV/r + RAL, being 58% in SG. Sixty percent received DRV/r 800/100 mg dose (rest, 600/100 mg). The median (IQR) age and CD4+ T-cell count were: 52 (42-58) years, and 373 cell/µL (202-642). Ninety-eight percent were ART-experienced with a median of 3 (IQR 2-5) prior treatments. Main reasons for switch (SG) were renal (57%), cardiovascular (54%) and bone (14%) comorbidities. Median exposure to DRV/r + RAL was 18 months. Among patients in SG, 98% and 96% had undetectable VL at 6 and 12 months; in the VG, 89% and 87% had undetectable VL at 6 and 12 months. No patient required suspension due to toxicity/ intolerance. CONCLUSION: In this cohort of mostly experienced HIV-infected patients, FDC DRV/r + RAL was effective and safe. Such therapy may be considered an option for patients with comorbid conditions and/or with multidrug-resistant HIV. Sociedad Española de Quimioterapia 2020-12-03 2021 /pmc/articles/PMC7876904/ /pubmed/33267555 http://dx.doi.org/10.37201/req/090.2020 Text en © The Author 2020 https://creativecommons.org/licenses/by-nc/4.0/ Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
spellingShingle Brief Report
Rombini, Fernanda
Cecchini, Diego M.
Ballivian, Jamile
Huberman, Mara
Urueña, Analía
Cassetti, Isabel
Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title_full Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title_fullStr Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title_full_unstemmed Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title_short Dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with HIV in Argentina
title_sort dual therapy with raltegravir plus a fixed dose combination of darunavir/ritonavir in people living with hiv in argentina
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7876904/
https://www.ncbi.nlm.nih.gov/pubmed/33267555
http://dx.doi.org/10.37201/req/090.2020
work_keys_str_mv AT rombinifernanda dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina
AT cecchinidiegom dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina
AT ballivianjamile dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina
AT hubermanmara dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina
AT uruenaanalia dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina
AT cassettiisabel dualtherapywithraltegravirplusafixeddosecombinationofdarunavirritonavirinpeoplelivingwithhivinargentina